Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR New Investigator

University of Toronto

$300,000.00

Improving Medication Use, Health Care and Quality of Life Through Innovative Health Outcomes Research

EF 2008-09

Résumé
Administrative claims data are rich and provide information to study how drugs are used in the real-world, and thus also provide real-world drug safety and effectiveness data. We outline two pilot projects that will capitalize on administrative claims data from Ontario. First, valid estimates of the safety and effectiveness of therapeutics are required to help inform drug policy decision making. Unfortunately, results from claims-based observational studies are error-prone due to incomplete information. We will use innovative methods that supplement claims-based data with other data sources to examine the potential benefits of these analytic strategies in improving estimates of the safety and effectiveness of drugs. We will start by examining fracture outcomes among seniors. Second, we know that adherence to therapy for osteoporosis, hypertension and hypercholesterolemia is suboptimal. However, little information is available regarding the patterns of drug use or the implications of gaps in adherence to therapy for these conditions. We will study patterns of pharmacotherapy, predictors of large gaps in treatment and implications of gaps in adherence to therapy for these conditions, starting with osteoporosis. Results will help identify the burden of illness in the population related to suboptimal adherence, and may be used to help develop quality improvement interventions. Results from these pilot projects will help inform future innovative projects that will aim to reduce the burden of illness in the population due to adverse drug effects and failure to adhere to preventive pharmacotherapy. Results will be important to guide health policy, develop quality improvement interventions, reduce health care costs and ultimately reduce the burden of illness in the population due to adverse drug effects and suboptimal adherence to chronic pharmacotherapy.
Programme
CIHR New Investigator
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
170461
Name
Cadarette Suzanne M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Osteoporosis Canada (Toronto, Ontario)
Instname2
Aging
Theme2
Health systems / services
Prcname2
Health Research Salary A
Projecttitle
Improving Medication Use, Health Care and Quality of Life Through Innovative Health Outcomes Research
Programtype2
Salary Programs
Orgnameinp2
University of Toronto
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Aging; Disease Prevention; Health Services Research; Osteoporosis; Pharmacoepidemiology
Abstract
Administrative claims data are rich and provide information to study how drugs are used in the real-world, and thus also provide real-world drug safety and effectiveness data. We outline two pilot projects that will capitalize on administrative claims data from Ontario. First, valid estimates of the safety and effectiveness of therapeutics are required to help inform drug policy decision making. Unfortunately, results from claims-based observational studies are error-prone due to incomplete information. We will use innovative methods that supplement claims-based data with other data sources to examine the potential benefits of these analytic strategies in improving estimates of the safety and effectiveness of drugs. We will start by examining fracture outcomes among seniors. Second, we know that adherence to therapy for osteoporosis, hypertension and hypercholesterolemia is suboptimal. However, little information is available regarding the patterns of drug use or the implications of gaps in adherence to therapy for these conditions. We will study patterns of pharmacotherapy, predictors of large gaps in treatment and implications of gaps in adherence to therapy for these conditions, starting with osteoporosis. Results will help identify the burden of illness in the population related to suboptimal adherence, and may be used to help develop quality improvement interventions. Results from these pilot projects will help inform future innovative projects that will aim to reduce the burden of illness in the population due to adverse drug effects and failure to adhere to preventive pharmacotherapy. Results will be important to guide health policy, develop quality improvement interventions, reduce health care costs and ultimately reduce the burden of illness in the population due to adverse drug effects and suboptimal adherence to chronic pharmacotherapy.
Competitiondate
200809
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Cadarette, Suzanne M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~